SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for BIOMET INC (CIK 0000351346) — Dec 28, 2004

BIOMET INC (CIK 0000351346)
Date: Dec. 28, 2004 · CIK: 0000351346 · Accession: 0000000000-04-042072

AI Filing Summary & Sentiment

Date
December 14, 2004
Author
President and CEO
Form
UPLOAD
Company
BIOMET INC (CIK 0000351346)

Letter

Mail Stop 0306 December 14, 2004 Dane A. Miller, Ph.D. President and CEO Biomet Inc 56 East Bell Drive Warsaw, Indiana 46582

Re: Biomet Inc Form 10-K for the fiscal year ended May 31, 2004 Form 10-Q for the fiscal quarter ended August 31, 2004 Forms 8-K for 2004 File No. 1-15601

Dear Dr. Miller:

We have reviewed your filings and have the following comments. We have limited our review to only your financial statements and related disclosures and will make no further review of your documents. Where indicated, we think you should revise your documents in response to these comments in all future filings with the Commission. If you disagree, we will consider your explanation as to why our comment is inapplicable or a revision is unnecessary. Please be as detailed as necessary in your explanation. In some of our comments, we may ask you to provide us with supplemental information so we may better understand your disclosure. After reviewing this information, we may or may not raise additional comments.

Please understand that the purpose of our review process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filing. We look forward to working with you in these respects. We welcome any questions you may have about our comments or on any other aspect of our review. Feel free to call us at the telephone numbers listed at the end of this letter.

Dr. Dane A. Miller December 14, 2004 Page 2

Form 8-K filed on September 17, 2004 and Amended on September 21,

1. We note that you present your non-GAAP measures in the form of an Adjusted Statement of Operations. That format may be confusing to investors as it also reflects several non-GAAP measures, including adjusted cost of sales, adjusted gross profit, adjusted R&D, adjusted operating income, adjusted income before taxes and minority interest and adjusted net income, which have not been described to investors. In fact, it appears that management does not use these non-GAAP measures but they are shown here as a result of the presentation format. Please note that Instruction 2 to Item 2.02 of Form 8-K requires that when furnishing information under this item you must provide all the disclosures required by paragraph (e)(1)(i) of Item 10 of Regulation S-K, including a reconciliation to the directly comparable GAAP measure for each non-GAAP measure presented and explain why you believe the measures provide useful information to investors. These disclosures must be included in the Form 8-K itself. * In future filings, to eliminate investor confusion, please remove the Adjusted Statement of Operations and disclose only those non- GAAP measures used by management with the appropriate reconciliations. * Otherwise, confirm that you will revise your Forms 8-K in future periods to provide all the disclosures required by Item 10(e)(1)(i) of Regulation S-K for each non-GAAP measure presented in the statement, and provide us with a sample of your proposed disclosure. We may have further comment.

Form 10-Q for the period ended August 31, 2004

2. We note that you present and discuss several non-GAAP measures in your results of operations, including an adjusted net sales, net U.S - based revenues, net foreign revenues excluding the impact of foreign currency and the impact of acquisitions, cost of sales adjusted for the current period impact of inventory step-up relating to acquisitions, and operating income adjusted for acquisition related expenses. In future filings, please consider revising MD&A to disclose and quantify the impact of these transactions on your US GAAP results. For example, you could indicate that the increase in net sales for the period reflected the impact of foreign currency fluctuations of $XX million and the impact of sales from the newly acquired businesses of $XX million.

Dr. Dane A. Miller December 14, 2004 Page 3

If you continue to provide these non-GAAP measures, please revise future filings to fully comply with Item 10(e) of Regulation S-K, including a reconciliation to the directly comparable GAAP measure for each non-GAAP measure presented, an explanation of why you believe the measures provide useful information to investors, and a statement disclosing the additional purposes for each of the non- GAAP measures.

* * * * * * *

As appropriate, please respond to these comments within 15 business days or tell us when you will provide us with a response. Please furnish a response letter that keys your responses to our comments and provides the requested supplemental information. Confirm that you will comply with these comments in all future filings with the Commission. Detailed response letters greatly facilitate our review. Please file your response letter on EDGAR under the label "CORRESP." Please understand that we may have additional comments after reviewing your responses to our comments and the requested supplemental information. When sending supplemental information regarding this filing, please include the following ZIP+4 code in our address: 20549-0306.

You may contact Jeanne Bennett at (202) 942-1915, or me at (202) 942-1931, if you have questions regarding our comments. In our absence you may contact Brian R. Cascio, Accounting Branch Chief, at (202) 942-1791.

Sincerely,
Angela J. Crane
Reviewing Accountant

Show Raw Text
<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>

Mail Stop 0306
		                    December 14, 2004

Dane A. Miller, Ph.D.
President and CEO
Biomet Inc
56 East Bell Drive
Warsaw, Indiana 46582

Re:	Biomet Inc
	Form 10-K for the fiscal year ended May 31, 2004
	Form 10-Q for the fiscal quarter ended August 31, 2004
	Forms 8-K for 2004
	File No.  1-15601

Dear Dr. Miller:

      We have reviewed your filings and have the following
comments.
We have limited our review to only your financial statements and
related disclosures and will make no further review of your
documents.  Where indicated, we think you should revise your
documents in response to these comments in all future filings with
the Commission.  If you disagree, we will consider your
explanation
as to why our comment is inapplicable or a revision is
unnecessary.
Please be as detailed as necessary in your explanation.  In some
of
our comments, we may ask you to provide us with supplemental
information so we may better understand your disclosure.  After
reviewing this information, we may or may not raise additional
comments.

	Please understand that the purpose of our review process is
to
assist you in your compliance with the applicable disclosure
requirements and to enhance the overall disclosure in your filing.
We look forward to working with you in these respects.  We welcome
any questions you may have about our comments or on any other
aspect
of our review.  Feel free to call us at the telephone numbers
listed
at the end of this letter.

Dr. Dane A. Miller
December  14, 2004
Page 2

Form 8-K filed on September 17, 2004 and Amended on September 21,
2004

1. We note that you present your non-GAAP measures in the form of
an
Adjusted Statement of Operations.  That format may be confusing to
investors as it also reflects several non-GAAP measures, including
adjusted cost of sales, adjusted gross profit, adjusted R&D,
adjusted
operating income, adjusted income before taxes and minority
interest
and adjusted net income, which have not been described to
investors.
In fact, it appears that management does not use these non-GAAP
measures but they are shown here as a result of the presentation
format.  Please note that Instruction 2 to Item 2.02 of Form 8-K
requires that when furnishing information under this item you must
provide all the disclosures required by paragraph (e)(1)(i) of
Item
10 of Regulation S-K, including a reconciliation to the directly
comparable GAAP measure for each non-GAAP measure presented and
explain why you believe the measures provide useful information to
investors.  These disclosures must be included in the Form 8-K
itself.
* In future filings, to eliminate investor confusion, please
remove
the Adjusted Statement of Operations and disclose only those non-
GAAP
measures used by management with the appropriate
reconciliations.
* Otherwise, confirm that you will revise your Forms 8-K in future
periods to provide all the disclosures required by Item
10(e)(1)(i)
of Regulation S-K for each non-GAAP measure presented in the
statement, and provide us with a sample of your proposed
disclosure.
We may have further comment.

Form 10-Q for the period ended August 31, 2004

2. We note that you present and discuss several non-GAAP measures
in
your results of operations, including an adjusted net sales, net
U.S
- based revenues,  net foreign revenues excluding the impact of
foreign currency and the impact of acquisitions, cost of sales
adjusted for the current period impact of inventory step-up
relating
to acquisitions, and operating income adjusted for acquisition
related expenses.  In future filings, please consider revising
MD&A
to disclose and quantify the impact of these transactions on your
US
GAAP results.  For example, you could indicate that the increase
in
net sales for the period reflected the impact of foreign currency
fluctuations of $XX million and the impact of sales from the newly
acquired businesses of $XX million.

Dr. Dane A. Miller
December  14, 2004
Page 3

If you continue to provide these non-GAAP measures, please revise
future filings to fully comply with Item 10(e) of Regulation S-K,
including a reconciliation to the directly comparable GAAP measure
for each non-GAAP measure presented, an explanation of why you
believe the measures provide useful information to investors, and
a
statement disclosing the additional purposes for each of the non-
GAAP
measures.

*  *  *  *  *  *  *

      As appropriate, please respond to these comments within 15
business days or tell us when you will provide us with a response.
Please furnish a response letter that keys your responses to our
comments and provides the requested supplemental information.
Confirm that you will comply with these comments in all future
filings with the Commission.  Detailed response letters greatly
facilitate our review.  Please file your response letter on EDGAR
under the label "CORRESP."  Please understand that we may have
additional comments after reviewing your responses to our comments
and the requested supplemental information.  When sending
supplemental information regarding this filing, please include the
following ZIP+4 code in our address:  20549-0306.

      You may contact Jeanne Bennett at (202) 942-1915, or me at
(202) 942-1931, if you have questions regarding our comments.  In
our
absence you may contact Brian R. Cascio, Accounting Branch Chief,
at
(202) 942-1791.

      Sincerely,

								Angela J. Crane
      							Reviewing Accountant

??

??

??

??

</TEXT>
</DOCUMENT>